ATE147993T1 - Zytomodulierte konjugate enthaltend spezifische bindungspaargliedern - Google Patents

Zytomodulierte konjugate enthaltend spezifische bindungspaargliedern

Info

Publication number
ATE147993T1
ATE147993T1 AT92303618T AT92303618T ATE147993T1 AT E147993 T1 ATE147993 T1 AT E147993T1 AT 92303618 T AT92303618 T AT 92303618T AT 92303618 T AT92303618 T AT 92303618T AT E147993 T1 ATE147993 T1 AT E147993T1
Authority
AT
Austria
Prior art keywords
conjugates
cytomodulated
specific binding
binding pairs
containing specific
Prior art date
Application number
AT92303618T
Other languages
English (en)
Inventor
Philippe Pouletty
Original Assignee
Sangstat Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24772845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE147993(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sangstat Medical Corp filed Critical Sangstat Medical Corp
Application granted granted Critical
Publication of ATE147993T1 publication Critical patent/ATE147993T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Detergent Compositions (AREA)
  • Medicinal Preparation (AREA)
AT92303618T 1991-04-23 1992-04-22 Zytomodulierte konjugate enthaltend spezifische bindungspaargliedern ATE147993T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69053091A 1991-04-23 1991-04-23

Publications (1)

Publication Number Publication Date
ATE147993T1 true ATE147993T1 (de) 1997-02-15

Family

ID=24772845

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92303618T ATE147993T1 (de) 1991-04-23 1992-04-22 Zytomodulierte konjugate enthaltend spezifische bindungspaargliedern

Country Status (7)

Country Link
EP (1) EP0510949B2 (de)
JP (1) JP3105629B2 (de)
AT (1) ATE147993T1 (de)
CA (1) CA2066810A1 (de)
DE (1) DE69216899T3 (de)
DK (1) DK0510949T3 (de)
ES (1) ES2099211T5 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858363A (en) * 1990-07-20 1999-01-12 Pharmacia & Upjohn Ab Target specific antibody-superantigen conjugates and their preparation
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
EP0602290B1 (de) * 1992-12-04 1999-08-25 ConjuChem, Inc. Antikörper-konjugiertes-Hepatitis B-Oberflächenantigen und dessen Verwendung
DE69726674T2 (de) * 1996-04-10 2004-10-21 Sangstat Medical Corp Zellmodulierende konjugate aus elementen aus spezifischen bindungspaaren
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6096725A (en) * 1997-07-02 2000-08-01 Neose Technologies, Inc. Methods of using αGal oligosaccharides as immune system targeting agents
GB9724838D0 (en) * 1997-11-26 1998-01-21 Franks Christopher R Compositions
ATE414536T1 (de) 1998-08-11 2008-12-15 Biogen Idec Inc Kombinationstherapien gegen b-zell-lymphome beinhaltend die verabreichung von anti-cd20- antikörpern
EP1949910A1 (de) * 1998-11-09 2008-07-30 Biogen Idec, Inc. Behandlung von CLL unter Verwendung chimärer Anti-CD20-Antikörper
PT1149111E (pt) 1999-01-06 2009-11-19 Univ Southern California Processo e composição para a inibição da angiogénese
US7829064B2 (en) 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US8119101B2 (en) 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
DE60042487D1 (de) 1999-07-13 2009-08-13 Univ Southern California Methode und zusammensetzung zur angiogenese-inhibierung mit antagonisten gegen mmp-9 und beta1-integrine
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
HUP0300421A2 (hu) 2000-03-31 2003-06-28 Purdue Research Foundation Kezelési eljárás ligand-immunogén konjugátumok felhasználásával
EP2428226A1 (de) 2001-10-22 2012-03-14 The Scripps Research Institute Verbindungen zum Targeting von Antikörpern
US7390885B2 (en) 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US7488792B2 (en) 2002-08-28 2009-02-10 Burnham Institute For Medical Research Collagen-binding molecules that selectively home to tumor vasculature and methods of using same
WO2004045512A2 (en) 2002-11-15 2004-06-03 Genmab A/S Human monoclonal antibodies against cd25
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
CN1747970A (zh) 2003-02-06 2006-03-15 三肽公司 抗原/抗体或配体/受体糖基化的特异性交换剂
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US8883160B2 (en) 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US10202430B2 (en) * 2007-10-18 2019-02-12 Mayo Foundation For Medical Education And Research IgM-mediated receptor clustering and cell modulation
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
US9192664B2 (en) 2011-12-05 2015-11-24 Immunomedics, Inc. Therapeutic use of anti-CD22 antibodies for inducing trogocytosis
AU2013360335B2 (en) 2012-12-13 2017-12-07 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9107960B2 (en) 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CN107428837A (zh) 2015-04-22 2017-12-01 免疫医疗公司 循环trop‑2阳性癌细胞的分离、检测、诊断和/或鉴定
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
US20170224837A1 (en) 2016-02-10 2017-08-10 Immunomedics, Inc. Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
JP7379795B2 (ja) 2016-04-27 2023-11-15 イミューノメディクス、インコーポレイテッド チェックポイント阻害薬に再発／耐性を示す腫瘍を治療するための抗Ｔｒｏｐ－２－ＳＮ－３８抗体薬物複合体の効果
WO2018183041A1 (en) 2017-03-27 2018-10-04 Immunomedics, Inc. Treatment of trop-2 expressing triple negative breast cancer with sacituzumab govitecan and a rad51 inhibitor
WO2018187074A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0180171B1 (de) † 1984-10-31 1992-04-08 Massachusetts Institute Of Technology Verfahren zum Sensibilisieren einer Zielzelle zum Lysen durch cytotoxische T-Lymphkörperchen
GB8626413D0 (en) † 1986-11-05 1986-12-03 Gilliland L K Antibodies
DE3880766D1 (de) * 1987-09-02 1993-06-09 Ciba Geigy Ag Konjugate von interferon alpha mit immunglobulinen.
DK8189A (da) * 1988-01-12 1989-07-13 Bunge Australia Antigen-antistof-konjugater, deres fremstilling og anvendelse
EP0334300A1 (de) † 1988-03-21 1989-09-27 Neorx Corporation Verwendung von monoklonalen Antikörpern und deren Konjugaten als Leitgruppen zum Transport von sensibilisierten Effektorzellen an Tumorstellen
DE3825615A1 (de) † 1988-07-28 1990-02-01 Behringwerke Ag Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung
KR900005995A (ko) * 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
GB8907310D0 (en) † 1989-03-31 1989-05-17 Medical Res Council Heteroconjugates
ZA902949B (en) * 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
JPH04506662A (ja) * 1989-07-14 1992-11-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
EP0547163B1 (de) * 1990-08-29 2002-02-06 Centre Hospitalier Regional De Nantes An stabile proteinkernstruktur gebundene proteinpolyliganden

Also Published As

Publication number Publication date
EP0510949B2 (de) 2003-04-02
ES2099211T3 (es) 1997-05-16
EP0510949A3 (de) 1992-12-09
EP0510949B1 (de) 1997-01-22
DE69216899T2 (de) 1997-06-12
EP0510949A2 (de) 1992-10-28
DK0510949T3 (da) 1997-07-28
JPH07173071A (ja) 1995-07-11
JP3105629B2 (ja) 2000-11-06
DE69216899D1 (de) 1997-03-06
ES2099211T5 (es) 2004-02-01
DE69216899T3 (de) 2004-01-15
CA2066810A1 (en) 1992-10-24

Similar Documents

Publication Publication Date Title
ATE147993T1 (de) Zytomodulierte konjugate enthaltend spezifische bindungspaargliedern
DE69726674T2 (de) Zellmodulierende konjugate aus elementen aus spezifischen bindungspaaren
FI103410B1 (fi) Starburst-konjugaatteja
DE3782394D1 (de) Immobilisiertes, physiologisch aktives material.
DE68912318D1 (de) Membranverpackung.
NO880626L (no) Fenol-stabiliserte mikrobiocidpreparater.
GR1000118B (el) Συνθεσις 1,2-διοξετανων & ενδιαμεσαι ουσιαι δι αυτην.
NO894408D0 (no) Hvirvelstroemapparat for materialproevning.
NO881077D0 (no) Kjemo-radio-immuno-konjugater.
NL191733B (nl) Overbrenginrichting voor voorwerpen, zoals eieren.
IT8019740A0 (it) Derivati benzoazepinici.
FI894211A0 (fi) Mikrobiologiskt foerfarande foer framstaellning av agrokemiskt anvaendbara aktivaemnen.
BG40952A3 (en) Herbicide means
NO883886L (no) Flammehemmende ethylencopolymermateriale.
GR1000098B (el) Παραγωγα διοξαζοκινης, παρασκευη των και συνθεσεις που τα περιεχουν.
FI880795A0 (fi) Banformat material, speciellt foer undertak.
FI855149A (fi) Nya n-(2-hydroxialkyl)aminosyror och deras derivat, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska preparat.
DE3771338D1 (de) Aus partikeln bestehendes steriles material.
NO881932L (no) Anordning for utmatning av korn- eller stykkeformet materiale.
IT8803327A0 (it) Centrale rischi prestiti personali e fiduciari c.r.p. p.f.
ATE95673T1 (de) Getreidezusammensetzung.
ES223724Y (es) Enganche perfeccionado entre laminas de material plastico.
NO885065L (no) Fremgangsmaate for aa krystallisere termoplastmateriale.
ATE81325T1 (de) Verpackung fuer kleinteile.
ATE91548T1 (de) Biosensoren.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0510949

Country of ref document: EP

REN Ceased due to non-payment of the annual fee